||The purpose of this project is to prospectively define hyper- and hypo-inflammatory phenotypes in patients with ARDS and determine clinical outcomes associated with each phenotype.
Objective 1: Assess the clinical outcomes in patients with ARDS according to their prospectively defined inflammatory phenotype determined using a POC assay.
Objective 2: (i) Assess the agreement of the phenotype allocation using a POC assay and the clinical study dataset
(ii) Assess the stability of phenotype allocation over time
(iii) Feasibility of delivering a POC assay in the NHS intensive care setting